Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies ("the Agreement"). The Agreement is based on a basic agreement on business collaboration in the field of immunoassay which the two companies signed in October 2023. In October 2023, Fujirebio and Sysmex entered into a basic agreement on business collaboration In October 2023, the two companies entered into a basic agreement on Business collaboration in the field of immuniassay, in a bid to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay.

To promote specific initiatives, in November 2023, the two companies signed a Contract Development and Manufacturing Organization (CDMO) agreement related to dedicated reagents for the HISCL??-Series automated immunoassay system, involving the development of reagents for cerebral-spinal fluid-based and blood-based testing in the field of neurodegenerative diseases, including Alzheimer's disease. Under the terms of the Agreement, Fujirebio andSysmex will mutually supply a wide range of reagent materials owned by each company, mainly antigens and antibodies, which are the main raw materials of immunoassay reagents. This will enable the CDMO to accelerate reagent development, reduce costs, and maximize the value of raw material assets, as well as build a stable supply system for future global demand growth and prepare for raw material procurement risk in the event of an emergency.

By strengthening cooperation in the area of reagent materials, the two companies will promote the mutual utilization of each company's high-quality reagent materials, and will further work together in the future with a view to developing new parameters and new technologies.